Tarsus Pharmaceuticals Balance Sheet
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tarsus Pharmaceuticals financial position
At the end of fiscal 2025, Tarsus Pharmaceuticals reported total assets of $562.2 million, up 49.1% from a year earlier against total liabilities of $218.7 million. Shareholders' equity stood at $343.4 million, or 61.1% of assets. The company held $183.6 million in cash and equivalents against $72.4 million of debt, a net cash position of $111.2 million.
The current ratio (current assets divided by current liabilities) was 3.85, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.21.
Summary generated from market data by MetaCap's automated system. Methodology
Tarsus Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 183.64M | 94.82M | 224.95M | 71.66M | 171.33M | 168.13M | 57.95M | 2.38M |
| Short-Term Investments | 233.63M | 196.56M | 2.50M | 145.37M | 483.00K | 0 | — | — |
| Receivables | 85.06M | 46.76M | 16.62M | 0 | 0 | 0 | — | — |
| Inventory | 4.37M | 2.62M | 3.11M | 0 | — | — | — | — |
| Total Current Assets | 522.78M | 356.70M | 256.13M | 225.38M | 175.95M | 170.66M | 58.03M | — |
| Property, Plant & Equipment | 11.66M | 2.31M | 1.47M | 957.00K | 755.00K | 548.00K | 154.00K | — |
| Intangible Assets | 7.37M | 8.33M | 3.87M | 0 | — | — | — | — |
| Long-Term Investments | 3.87M | 3.00M | 631.00K | 371.00K | 0 | — | — | — |
| Total Assets | 562.16M | 376.99M | 265.49M | 227.86M | 178.91M | 171.97M | 58.32M | — |
| Accounts Payable | 16.39M | 9.42M | 17.77M | 5.50M | 2.86M | 2.24M | 456.00K | — |
| Total Current Liabilities | 135.69M | 80.61M | 36.94M | 15.43M | 11.48M | 5.39M | 819.00K | — |
| Long-Term Debt | 72.44M | 71.84M | 29.82M | 19.43M | 0 | — | — | — |
| Total Liabilities | 218.73M | 152.46M | 68.50M | 34.96M | 12.18M | 5.99M | 919.00K | — |
| Shareholders' Equity | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M | 165.98M | -6.00M | -1.35M |
| Retained Earnings | -426.63M | -360.21M | -244.66M | -108.76M | -46.67M | -32.84M | -6.03M | — |
| Total Debt | 72.44M | 71.84M | 29.82M | 19.43M | 0 | — | — | — |
| Net Cash (Debt) | 344.83M | 219.53M | 197.62M | 197.59M | 171.81M | 168.13M | 57.95M | 2.38M |
| Shares Outstanding | 42.55M | 38.35M | 34.21M | 26.70M | 20.70M | 20.32M | 2.65M | — |
This table shows 8 annual periods of Tarsus Pharmaceuticals's balance sheet, from FY 2025 back to FY 2018, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TARS's reporting calendar. What is a balance sheet?